StockNews.com Begins Coverage on Eiger BioPharmaceuticals (NASDAQ:EIGR)

Research analysts at StockNews.com assumed coverage on shares of Eiger BioPharmaceuticals (NASDAQ:EIGR) in a research note issued on Friday. The firm set a “sell” rating on the biotechnology company’s stock.

Eiger BioPharmaceuticals Price Performance

The company has a fifty day moving average of $4.52 and a 200 day moving average of $6.86. Eiger BioPharmaceuticals has a 12 month low of $1.10 and a 12 month high of $43.35. The stock has a market cap of $2.55 million, a P/E ratio of -0.03 and a beta of 1.83.

Eiger BioPharmaceuticals Company Profile

Eiger BioPharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection.